Robert Kushner: GLP-1 appears to be a strong enough regulator, dealing with the appetite dysregulation, to really harmonize my understanding harmonize all these other factors you're talking about
Larbig W, Gerber WD, Kluck M, Schoenenberger GA
Treatment is HSA/FSA eligible and available in all 50 states without insurance
Works for compounded tirzepatide, Mounjaro, and Zepbound
However, the risks associated with its use are non-trivial, particularly given the lack of regulatory approval and the potential for serious side effects
Seek urgent medical attention if you develop persistent severe abdominal pain (especially if radiating to the back), with or without vomiting, as these could be symptoms of pancreatitisa rare but serious potential complication of GLP-1 based therapies